An interaction study in 15 males was conducted between olanzapine (OL), an atypical antipsychotic, and warfarin (W) as a 3-way randomized crossover. The S-isomer of W is a probe for CYP2C9 metabolism. Each subject ingested 10mg OL or 20mg (R/S) W alone, and OL+W combination (OL+) as single doses (10 day washout interposed). OL+ did not potentiate adverse events of OL or W or anticoagulant effects of W. Stereo specific assays for RW and SW (HPLC-UV) and OL (HPLC-EC) were done. RW, SW and OL noncompartmental pharmacokinetics (PK) were assessed. Statistical evaluation by ANOVA for crossover design showed no significant (p>0.05) differences between OL or W versus OL+. PK Variables OL OL+ RW RW+ SW SW+ Cmax ng/mL 10.7 9.5 1280 1210 1330 1250 T1/2 hr 27.9 30.0 37.7 39.0 131.3 31.3 AUCμg×hr/mL .377 .353 48.5 47.4 36.3 35.8 CL/FF L/hr 29.8 30.9 0.21 0.22 0.28 0.29 Vβ/FF L 1150 1300 11.4 12.0 12.6 12.7 W PK were unaffected by concomitant OL and vice versa. OL does not inhibit CYP2C9.
|Original language||English (US)|
|Number of pages||1|
|Journal||Clinical Pharmacology and Therapeutics|
|State||Published - Dec 1 1997|
ASJC Scopus subject areas
- Pharmacology (medical)